Scarica l'app Stockscreener
277.36
0.50%
-1.39
Dopo l'orario di chiusura:
277.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Precedente Chiudi:
$278.75
Aprire:
$278.75
Volume 24 ore:
167.85K
Relative Volume:
0.56
Capitalizzazione di mercato:
$8.04B
Reddito:
$290.51M
Utile/perdita netta:
$89.16M
Rapporto P/E:
92.76
EPS:
2.99
Flusso di cassa netto:
$119.18M
1 W Prestazione:
+0.93%
1M Prestazione:
+9.99%
6M Prestazione:
+87.90%
1 anno Prestazione:
+74.37%
Intervallo 1D:
$275.07
$281.28
Intervallo di 1 settimana:
$271.70
$294.64
Portata 52W:
$122.80
$295.98
Krystal Biotech Inc Stock (KRYS) Company Profile
Nome
Krystal Biotech Inc
Settore
Industria
Telefono
(412) 586-5830
Indirizzo
2100 WHARTON STREET, PITTSBURGH, PA
Confronta KRYS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
277.36 | 8.08B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-05 | Iniziato | Jefferies | Buy |
| 2024-08-06 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2023-02-28 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-18 | Iniziato | BofA Securities | Buy |
| 2021-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-06-04 | Iniziato | Evercore ISI | Outperform |
| 2019-09-24 | Iniziato | Goldman | Neutral |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-24 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-30 | Iniziato | Guggenheim | Buy |
| 2018-09-11 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
Krystal Biotech, Inc. $KRYS Shares Acquired by EFG Asset Management North America Corp. - MarketBeat
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Clear Street raises Krystal Biotech stock price target on KB801 potential - Investing.com Canada
Are You Looking for a Top Momentum Pick? Why Krystal Biotech, Inc. (KRYS) is a Great Choice - Yahoo Finance
Krystal Biotech, Inc. $KRYS Shares Sold by Maryland State Retirement & Pension System - MarketBeat
SG Americas Securities LLC Cuts Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Bank of America Increases Krystal Biotech (NASDAQ:KRYS) Price Target to $318.00 - MarketBeat
KRYS Sees New Price Target as B of A Securities Raises Outlook | - GuruFocus
Nasdaq Moves: Is Caribou Biosciences Inc. backed by strong institutional buyingSell Signal & Low Drawdown Investment Strategies - baoquankhu1.vn
Rate Cut: What drives Krystal Biotech Incs stock price2025 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
What does Wall Street think about Krystal Biotech (KRYS)? - MSN
Krystal Biotech, Inc. (KRYS) Stock Analysis: Evaluating the Healthcare Innovator’s Growth Potential - directorstalkinterviews.com
What Does Wall Street Think About Krystal Biotech (KRYS)? - Finviz
Krystal Biotech (KRYS) Is Up 9.0% After Positive Interim Data From Inhaled CF Gene Therapy Study - Sahm
Krystal Biotech gets expanded FDA approval for Vyjuvek - MSN
Krystal Biotech: Beyond VYJUVEK Commercialization (NASDAQ:KRYS) - Seeking Alpha
Recent price trend in Krystal Biotech (KRYS) is your friend, here's why - MSN
Assessing Krystal Biotech (KRYS) Valuation After Strong Recent Share Price Momentum - Sahm
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Update and CORAL-3 Plans - Sahm
Krystal Biotech Reports Strong Q3 2025 Performance - MSN
Krystal Biotech rises on new phase 1 data for cystic fibrosis asset - MSN
Activity Recap: Will Krystal Biotech Inc outperform small cap indexes2025 Institutional Moves & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Krystal Biotech (KRYS) Price Target Increased by 18.96% to 269.93 - Nasdaq
Krystal Biotech (BIT:1KRYS) Price Target Increased by 19.80% to 226.45 - Nasdaq
Movement Recap: What is Krystal Biotech Inc.’s market position2025 Short Interest & Daily Profit Maximizing Tips - baoquankhu1.vn
KRYS Stock: Citigroup Raises Price Target to $336, Maintains Buy - GuruFocus
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives - sharewise.com
Citigroup Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price - MarketBeat
Avoiding Lag: Real-Time Signals in (KRYS) Movement - Stock Traders Daily
Krystal Biotech stock maintains Buy rating at H.C. Wainwright on strong revenue - Investing.com Canada
Krystal Biotech outlines rare disease growth strategy update - TipRanks
Krystal Biotech, Inc. (KRYS) Stock Analysis: Navigating A Promising 4.05% Potential Upside - DirectorsTalk Interviews
Credo Technology Group Holding And 2 Insider Picks For Strong Growth - Yahoo Finance
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Krystal Biotech Reports ~$389M 2025 VYJUVEK Revenue, $955M Cash Reserves - Nasdaq
Krystal Biotech expects Vyjuvek net revenue of $106 million to $107 million for Q4 2025 - marketscreener.com
Rpt-Krystal Biotech Expects VYJUVEK Net Revenue Of $106 Million To $107 Million For Q4 2025 - TradingView — Track All Markets
Krystal Biotech Announces Preliminary 4Q 2025 VYJUVEK Revenue of $106-$107 Million and Strategic Vision for Growth in Rare Disease Market | KRYS Stock News - Quiver Quantitative
Krystal Biotech expects net revenue of $106 million to $107 million for Q4 2025 - marketscreener.com
Krystal Biotech Expects Net Revenue Of $106 Million To $107 Million For Q4 2025 - TradingView — Track All Markets
Inside one company's plan to reach 10,000 rare disease patients - Stock Titan
Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of "Buy" by Analysts - MarketBeat
Krystal Biotech Reports $107M VYJUVEK Revenue for Q4 2025 - Intellectia AI
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing - Yahoo Finance
Krystal Biotech stock hits all-time high at 265.99 USD By Investing.com - Investing.com Nigeria
Is Krystal Biotech (KRYS) Still Attractively Priced After Its Strong Multi Year Share Price Run - Yahoo Finance
Krystal Biotech (NASDAQ:KRYS) Reaches New 1-Year High Following Analyst Upgrade - MarketBeat
KRYS: TD Cowen Raises Price Target and Maintains Buy Rating | KR - GuruFocus
Assessing Krystal Biotech (KRYS) Valuation After Positive KB407 Cystic Fibrosis Trial Update - Yahoo Finance
Krystal Biotech (KRYS) Rises on Positive Phase 1 Data for Cystic Fibrosis Treatment - GuruFocus
Krystal Biotech (NASDAQ:KRYS) Stock Price Up 7%Still a Buy? - MarketBeat
Krystal Biotech Inc Azioni (KRYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):